Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxic injury

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Toxic injury. Displaying page 1 of 1.
    EudraCT Number: 2008-004771-22 Sponsor Protocol Number: Vs.12.11-07-2008 Start Date*: 2008-09-03
    Sponsor Name:Rigshospitalet, Kardiologisk afd
    Full Title: Prospective randomised dubbleblind placebocontrolled trial of calcium antagonist to prevent calcineurin induced nephropathy in lung transplanted patients
    Medical condition: kidney damage in ciclosporin treated lung transplant patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029155 Nephropathy toxic PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001838-29 Sponsor Protocol Number: TEATE Start Date*: 2015-01-08
    Sponsor Name:"G. d'Annunzio" University
    Full Title: PrevenTion of contrast‐inducEd nephroAThy with urinE alkalinization: the TEATE study
    Medical condition: contrast‐induced nephroathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022117 - Injury, poisoning and procedural complications 10010836 Contrast media reaction PT
    17.0 10038359 - Renal and urinary disorders 10029155 Nephropathy toxic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005682-12 Sponsor Protocol Number: H-2-2012_089 Start Date*: 2013-07-03
    Sponsor Name:Dept. of Clinical Immunology
    Full Title: THE EFFECT OF PLASMA ON THE ENDOTHELIUM IN CRITICAL ILLNESS
    Medical condition: Pilot study in healthy subjects with a perspective for treating of serious conditions such as sepsis, septic shock, trauma and severe haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10054438 Ischemia LLT
    16.0 100000004866 10019595 Hemorrhage, unspecified LLT
    16.0 100000004862 10040580 Shock septic LLT
    16.0 100000004863 10044461 Trauma LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003814-14 Sponsor Protocol Number: ML19498 Start Date*: 2006-03-13
    Sponsor Name:Unidad Integral de Investigación en Oncología, S.L.
    Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000707-81 Sponsor Protocol Number: VIPER-SEPSIS Start Date*: 2016-04-26
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000427-27 Sponsor Protocol Number: VIPER-SHOCK Start Date*: 2017-03-30
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006789-19 Sponsor Protocol Number: NephroD_2021 Start Date*: 2022-05-16
    Sponsor Name:USK w Opolu
    Full Title: Efficacy comparison of two doses of vitamin D3 in critically ill patients undergoing continuous renal replacement therapy - NephroD
    Medical condition: Vitamin D3 deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10047626 Vitamin D deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005441-38 Sponsor Protocol Number: F1K-MC-EVDP Start Date*: 2008-03-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) FR (Completed) BE (Completed) IT (Completed) PT (Completed) FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005721-39 Sponsor Protocol Number: I5B-MC-JGDN Start Date*: 2016-06-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-dose Ifosfamide in Pediatric Patients with Relapsed...
    Medical condition: Neoplasm Metastasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10049280 Solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005159-18 Sponsor Protocol Number: CRO2047 Start Date*: 2013-08-28
    Sponsor Name:Imperial College, London
    Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)
    Medical condition: Septic shock.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10028237 Multiple organ failure LLT
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001977-34 Sponsor Protocol Number: PHRC-N/2015/PR-01 Start Date*: 2017-06-23
    Sponsor Name:CHU de Nîmes
    Full Title: L-carnitine as an adjunct treatment for septic shock patients with acute kidney injury: a multicentre, randomized, 2-parallel group, superiority trial
    Medical condition: patients devant bénéficier d'un traitement pour choc septique, accompagné d'insuffisance rénale aigüe
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019974 10040580 Shock septic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001862-12 Sponsor Protocol Number: s63213 Start Date*: 2021-03-23
    Sponsor Name:University Hospitals Leuven, Clinical Trial Centre
    Full Title: Early administration of Vitamin C in patients with sepsis or septic shock in emergency departments: a multicentre, double blinded, randomized controlled trial: the C-EASIE trial.
    Medical condition: We will investigate the potential benefit of early administration of high doses of Vitamin C in addition to standard care in patients with sepsis or septic shock.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002935-27 Sponsor Protocol Number: ADVL1712 Start Date*: 2021-05-21
    Sponsor Name:National Cancer Institute
    Full Title: A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute...
    Medical condition: This trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024330 Leukemia acute LLT
    21.0 100000004864 10024349 Leukemia myeloid LLT
    21.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001785-14 Sponsor Protocol Number: STRESS-L Start Date*: 2017-11-09
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)
    Medical condition: Tachycardia in Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10040070 Septic shock PT
    20.0 10007541 - Cardiac disorders 10043071 Tachycardia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002073-26 Sponsor Protocol Number: 1125-ECIR Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy
    Medical condition: Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10043408 Therapeutic agent toxicity LLT
    26.1 10018065 - General disorders and administration site conditions 10067033 Drug side effect LLT
    24.0 10018065 - General disorders and administration site conditions 10061623 Adverse drug reaction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010551-26 Sponsor Protocol Number: D0102C00003 Start Date*: 2009-08-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a S...
    Medical condition: Phase I part of the study: Solid tumours that are refractory to standard therapies Phase II part of the study: trastuzumab- or lapatinib-ineligible patients with locally advanced (not amenable to s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 15:06:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA